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Mutations in the 81-bp rifampin resistance-determining region (RRDR) of the rpoB gene were analyzed by
DNA sequencing of 50 Mycobacterium tuberculosis clinical isolates (44 resistant and 6 sensitive) from various
parts of India. Fifty-three mutations of 18 different kinds, 17 point mutations and one deletion, were observed
in 43 of 44 resistant isolates. Three novel mutations and three new alleles within the RRDR, along with two
novel mutations outside the RRDR, are reported in this study.
Tuberculosis (TB), though curable, still remains a major
killer disease worldwide. The magnitude of the problem is
reflected in estimates of new cases, which are predicted to
number around 10 million in the year 2000 and 12 million by
2005 (7). Global prevalence of infection due to Mycobacterium
tuberculosis is 32%. Eighty percent of all new TB cases are
found in around 22 countries, with more than half the cases
occurring in 5 Southeast Asian countries (6). Thirty percent of
the world’s TB-infected population is in India. The enormity of
the problem has increased with the emergence of multidrug-
resistant (MDR) strains of M. tuberculosis. Dual infection with
human immunodeficiency virus and MDR TB is a virtual death
sentence in this era.
Rifampin (RIF) resistance serves as a surrogate marker for
the detection of MDR TB, as 90% of Rif r isolates are also
isoniazid resistant (5). RIF interferes with transcription and
elongation of RNA by binding to the DNA-dependent RNA
polymerase. It was observed that resistance to RIF follows a
single-step, high-level resistance pattern in which mutations
occur spontaneously at a frequency of 1029. The genetic basis
for RIF resistance in approximately 95% of the cases is due to
mutations in an 81-bp RIF resistance-determining region
(RRDR) of the rpoB gene, corresponding to codons 507 to 533
(Escherichia coli numbering system), which codes for the beta
subunit of the RNA polymerase of M. tuberculosis.
Different groups of workers from diverse regions of the
world (4, 8–12, 14, 16, 19, 20, 21, 23, 24) have thus far reported
around 65 substitutions, 12 deletions, and 4 insertions in the
RRDR of the rpoB gene. Only one of these earlier reports is
concerned with Indian isolates, and in that study rpoB muta-
tions were observed in three Rif r isolates (8). Determination of
the mutation patterns among large numbers of isolates from
different parts of India is essential, since this would help not
only in the design of a suitable diagnostic method for rapid
detection of MDR TB but also in the identification of any
hot-spot regions in the country for proper implementation of
TB control programs. It would also help in understanding
whether mutated alleles arise independently or due to the
spread of a particular genotype. Moreover, it is well known
that clinical isolates from southern India are very different
from isolates from other parts of the world. The former have
lower virulence in guinea pigs (2), higher susceptibility to hy-
drogen peroxide (13, 18) and thiophene-2-carboxylic acid hy-
drazide (TCH), lower sensitivity to p-aminosalicylic acid (17)
and thioacetazone, and an appreciably higher proportion of
phage type I (1). It is of interest to determine whether these
southern Indian isolates show any different kinds of mutations
in the RRDR region of the rpoB gene.
DNA sequencing of RRDR. The following are the results of
DNA sequencing of the RRDR of 44 Rif r isolates (35 of which
were isolated from patients from southern India) and 6 Rif s
isolates, all obtained from seven states in India.
(i) M. tuberculosis isolates. Forty-four Rif r and six Rif s
strains were isolated from 50 patients from seven states in
India. Of the 44 Rif r strains, the numbers isolated from each
state were as follows: Andhra Pradesh (AP), 6; Delhi, 1; Goa,
3; Kerala, 4; Karnataka, 5; Sikkim, 5; and Tamil Nadu (TN),
20. Of the six Rif s strains, four were obtained from patients
from TN, while two were from AP. The drug susceptibility
patterns of these isolates are shown in Table 1.
(ii) Determination of sensitivity to RIF. Conventional indi-
rect susceptibility testing was done using Lowenstein-Jensen
medium, and RIF sensitivity was determined by the MIC
method. Resistance was defined by a MIC equal to or greater
than 128 mg/liter.
(iii) Sequencing of the RRDR of the rpoB gene. The RRDR
of the rpoB gene was sequenced after amplification by PCR to
analyze the mutations associated with RIF resistance. Tem-
plate DNA for PCR was obtained using cetyltrimethylammo-
nium bromide (22). PCR was performed using primers rpo3 (59
CAGACGTTGATCAACATCCG 39) and rpo4 (59 TACGGC
GTTTCGATGAAC 39) to generate a 305-bp product, which
was purified and used for sequencing. A T7 Sequenase v 2.0
PCR product sequencing kit (Amersham Life Science) and
primer TR9 (59 TCGCCGCGATCAAGGAGT 39) were used
for manual sequencing. In brief, 1 ml of exonuclease I (10
U/ml) and 1 ml of shrimp alkaline phosphatase (2 U/ml) were
added to 7 ml of PCR amplification mixture, and the mixture
was incubated at 37°C for 15 min. The reaction mixture was
inactivated by heating to 80°C for 15 min. To 9 ml of treated
PCR product, 1 ml of primer (10 pmol/ml) was added, and the
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mixture was incubated at 100°C for 3 min, followed by snap
cooling. To this ice-cold annealed DNA mixture, 2 ml of 53 T7
Sequenase reaction buffer, 1 ml of 0.1 M dithiothreitol, 2 ml of
a 1:10-diluted labeling mixture, 5 mCi of [35S]dATP, and 2 ml
of T7 Sequenase v 2.0 DNA polymerase were added, and the
mixture was incubated at room temperature for 2 min. Ali-
quots of this mixture (3.5 ml each) were added to termination
tubes containing 2.5 ml of each termination mixture (G, A, T,
and C) and incubated at 37°C for 10 min. The reaction was
stopped by adding 4 ml of stop solution. Samples were heated
to 75°C for 2 min and then loaded onto a sequencing gel. An
automated sequencer (ABI Prism model 377 version 3.0) was
used with primer TR8 (59 TGCACGTCGCGGACCTCCA 39)
to confirm the sequence in reverse order. The data obtained
were compared with the sequence obtained from the database
at the Sanger Centre using the BLAST program (www.sanger
.ac.uk).
Molecular analysis. The MIC of RIF for all 44 Rif r isolates
was greater than 128 mg/liter, while the MIC of RIF for all six
Rif s isolates was less than 32 mg/liter. DNA sequence analysis
of the 44 Rif r isolates showed that 39 had a single mutation,
two had triple mutations, and two had quadruple mutations in
the 81-bp RRDR of the rpoB gene. One isolate did not contain
any mutation. Fifty-three mutations of 18 different kinds, 17
point mutations and one deletion, were observed (Table 2).
Two isolates from TN that contained four mutations had a
novel mutation of GCG to GCA at codon 532. In addition, one
of the two TN isolates had mutations at codon 518 (AAC to
CAC), codon 531 (TCG to TTG), and codon 533 (CTG to
CTT), while the other had mutations at codon 511 (CTG
to ATG), codon 512 (AGC to AGG), and codon 526 (CAC to
GAC). One isolate from AP that contained a triple mutation
had two mutations in codon 516 (GAC to AAA) and another
at codon 531 (TCG to TTG). This particular isolate also con-
tained a mutation outside the RRDR (CCC to CAC at codon
535). The other isolate that contained a triple mutation was
from TN and had mutations at codon 508 (ACC to AGC),
codon 512 (AGC to AGG), and codon 526 (CAC to GAC). In
Karnataka, four isolates had the same mutation, TCG to TTG,
at codon 531, while the fifth exhibited a mutation at codon 526,
CAC to GAC. None of the sensitive strains contained any
mutation.
Eighteen different types of mutations were identified in 44
Rif r M. tuberculosis clinical isolates. Ninety-five percent of
these were point mutations involving 10 codons, while only one
isolate had a deletion. The codons most frequently involved in
mutation were codon 531 (frequency, 53%) and codon 526
(19%). Among the different mutations seen at codon 531, the
mutation of TCG (Ser) to TTG (Leu) occurred at a very high
frequency, 49%. Matsiota-Bernard et al. (10) and Pozzi et al.
(14) found similarly high frequencies of this particular muta-
tion, 56 and 59%, respectively. Though mutation of CAC to
GAC at codon 526 occurred at frequencies of 30% in Italian
isolates (14) and 19% in Greek isolates (10), we found a low
frequency of this mutation, 6%. Previous workers have re-
ported a wide range of frequencies for these particular muta-
tions at codon 531 (20 to 71%) and codon 526 (0 to 30%) (14).
Ramaswamy and Musser (15) showed frequencies of 41 and
36% for various mutations occurring at codons 531 and 526,
respectively, in 478 isolates obtained from various parts of the
world. Billington et al. (3) observed that mutants isolated more
frequently in clinical practice have a higher mean relative fit-
ness and the prevalence of each mutant type depends on its
ability to survive. This might be the reason for the higher
occurrence of the mutation of TCG to TTG at codon 531 in
isolates in the present study from all the states except those
from AP, where codon 526 was the most involved. Five differ-
ent types of mutations were seen at codon 526 (Fig. 1). Hirano
et al. (8) reported mutations in Indian isolates at codon 531
(TCG to TGG) and codon 526 (CAC to GAC). No mutation
was observed in the RRDR of the six Rif s isolates analyzed in
this study. One isolate, although resistant to RIF, did not show
any mutation. Kapur et al. (9) also reported such observations.
The RIF resistance in these isolates may be due either to the
presence of a mutation elsewhere in this gene or to some other
resistance mechanism.
Mutations at codon 532 from GCG (Ala) to GCA (Ala) in
two isolates and at codon 508 from ACC (Thr) to AGC (Ser)
and deletion at codon 517 alone of CAG (Gln) have not been
reported previously. New alleles reported in this study include
mutations from AGC (Ser) to AGG (Arg) at codon 512, GAC
TABLE 1. Drug susceptibility patterns of MDR M. tuberculosis
strains isolated in India
No. of
strains
Susceptibility to indicated druga
INH RIF EMB STR
30 Rb R R R
6 R R R
6 R R
2 R R R
a INH, isoniazid; EMB, ethambutol; STR, streptomycin.
b R, resistant.
TABLE 2. Distribution of mutations by state found in the RRDR
of the rpoB gene in Rif r M. tuberculosis isolates from India
Codon no. Mutation Distribution by statea
508 ACC 3 AGCb TN, 1
511 CTG 3 CCG K, 1; TN, 1
CTG 3 ATG TN, 1
512 AGC 3 AGGc TN, 2
513 CAA 3 AAA G, 1
516 GAC 3 TACc S, 1
GAC 3 AAAd AP, 1
517 CAG 3 delb,e AP, 1
518 AAC 3 CAC TN, 1
526 CAC 3 CTC S, 1; TN, 2
CAC 3 TAC AP, 1; K, 1
CAC 3 GAC KA, 1; TN, 2
CAC 3 CGC AP, 1
CAC 3 ACC AP, 1
531 TCG 3 TGG S, 1; TN, 1
TCG 3 TTG S, 2; G, 2; K, 2; KA, 4;
AP, 2; D, 1; TN, 13
532 GCG 3 GCAb TN, 2
533 CTG 3 CTTc TN, 1
a KA, Karnataka; S, Sikkim; G, Goa; D, Delhi; K, Kerala.
b Novel mutation.
c New allele.
d Double mutations in the same codon.
e del, deletion.
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(Asp) to AAA (Lys) at codon 516, and CTG (Leu) to CTT
(Leu) at codon 533. New mutations outside the RRDR were
also seen in two isolates (GGG to GAG at codon 534 and CCC
to CAC at codon 535). Previous workers have also reported
mutations outside the RRDR (GAG to GCG at codon 504
[16], GAG to GAT at codon 541 [14], TCG to GCG at codon
553 [14], and ATC to TTC at codon 572 [24]).
In contrast to the results obtained by Taniguchi et al. (19),
our results showed high MICs for isolates with mutations at
codon 516 or codon 533. In fact, a high MIC (.128 mg/liter)
was demonstrated even for an isolate with a silent mutation at
codon 532.
Forty-three Rif r isolates in the present study either showed
a substitution(s) or a deletion in the RRDR. New alleles as
well as novel mutations within as well as outside the RRDR
have been found in this study. The majority of the mutations
map to codon 531, followed by codon 526. There was no
specific geographical clustering of isolates in terms of muta-
tions. Though the occurrence of mutations at codon 526 was
high in AP compared to that in other states, analysis with a
higher sample number needs to be done to arrive at a definitive
conclusion.
Despite the large number of mutations already reported in
other studies, the evidence of new mutations in this study
indicates that mutations continue to arise, probably due to the
ability of M. tuberculosis to adapt to drug exposure.
In this study, molecular analysis of the 81-bp RRDR of the
rpoB gene of 50 M. tuberculosis clinical isolates from various
parts of India was carried out and the mutations were identi-
fied. Three novel mutations and three new alleles within the
RRDR and two novel mutations outside the RRDR were
identified. Although the Indian isolates exhibited few distinct
characteristics, the pattern of mutations in the 81-bp RRDR is
similar to that reported for the majority of clinical isolates in
different parts of the world.
Tests like Inno-LiPA Rif.TB (Innogenetics, Zwijndrecht,
Belgium) rapidly identify clinical isolates as members of the M.
tuberculosis complex and determine the presence of point mu-
tations within the RRDR of the rpoB gene. Such tests basically
exploit the principle of hybridization, and the probes for such
tests are designed according to the expected mutations. If the
expected mutations or their frequencies of occurrence are dif-
ferent in different countries, such molecular diagnostic tests
will have to be slightly modified. Further, knowledge of the
mutations present in these isolates would help in the use of
rpoB genotyping as an epidemiological tool for Rif r M. tuber-
culosis isolates. rpoB genotyping can also be used for discrim-
ination of Rif r M. tuberculosis isolates with identical IS6110
fingerprints. Therefore, the new mutations reported here need
to be considered in the development of new molecular diag-
nostic methods to be implemented in India. This study, though
confirming the universal pattern of mutations in rpoB, also
reveals the presence of novel mutations and new alleles among
Indian isolates.
Nucleotide sequence accession numbers. The sequences
with novel mutations found in this study are deposited in
EMBL under accession numbers AJ297922, AJ297923, and
AJ297924; those with mutations in the new alleles are depos-
ited under accession numbers AJ297925, AJ297926, and
AJ297927; and those with mutations outside RRDR are de-
posited under accession numbers AJ297928 and AJ297929.
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